Indivior Pharmaceuticals Inc (INDV) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access INDV Annual Cash Flow →
The data below summarizes Indivior Pharmaceuticals Inc's cash flow activity from Jun 30 2025 to Jun 30 2026, enabling a period-by-period view of cash movement.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
6 Months
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income211.00
Depreciation & amortization4.00
Amortization of Other Assets1.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges8.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-3.00
R & D, Environmental and Other Expense0.00
Adjustments For Decrease IncreaseIn Other Assets0.00
Share-based Compensation20.00
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt-19.00
Adjustments For Sharebased Payments-
Adjustment For Settlement Of Tax On Employee Awards-
Adjustments For Decrease Increase In Inventories-
Adjustments For Increase Decrease In Trade And Other Payables-
Adjustments For Increase Decrease In Other Liabilities-
Income Taxes Refund Classified As Operating Activities-
Income Taxes Paid Classified As Operating Activities-
Equity Securities Fv Ni Unrealized Gain Loss-
Research And Development Asset Acquired Other Than Through Business Combination Written Off-
Increase Decrease In Estimated Litigation Liability-38.00
Income taxes0.00
Purchase Of Intangible Assets Classified As Investing Activities0.00
Increase (Decrease) in Accounts Receivable17.00
Adjustments For Decrease IncreaseIn Trade Account Receivable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital22.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-41.00
Discontinued operations0.00
Net Cash flow from Operating Activities220.00
Investing Activities
Capital Expenditures-27.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Held-to-maturity Securities9.00
Payments to Acquire Held-to-maturity Securities-8.00
Real Estate Investments0.00
Proceeds From Sale Of Equity Securities Fv Ni-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Purchase Of Financial Instruments Classified As Investing Activities0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-1.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-27.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-5.00
Long-term debt - borrowings489.00
Long-term debt - repayments-333.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-302.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-16.00
Other net1.00
Increase Decrease In Cash And Cash Equivalents-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-166.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow193.00
Total Cash Flow28.00
4 historic quarters locked

Sign in to unlock the full Indivior Pharmaceuticals Inc cash flow history.

About Indivior Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-051895

Figures are derived from filed reports and may be restated. Historical data is subject to revision.